Identifying barriers associated with enrollment of patients with lung cancer into clinical trials

Leora Horn, Vicki L. Keedy, Norma Campbell, Gabe Garcia, Amy Hayes, Brady Spencer, David P. Carbone, Alan Sandler, David H. Johnson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Enrollment of patients with lung cancer into clinical trials is required to accelerate the pace of new therapy development and contribute to a better understanding of the biological characteristics of cancer. Methods: We conducted a retrospective chart review of all patients seen by the thoracic medical oncology team at the Vanderbilt Ingram Cancer Center (VICC) from November 2005 to November 2008 to determine the barriers associated with patient enrollment in to clinical trials. Results: One thousand forty-three patient charts were audited: 32% of patients were eligible for enrollment, and 14% enrolled in a study. There were no significant differences in protocol availability or eligibility by sex, smoking status, or age. Patients living further from the cancer center were significantly less likely to have a study protocol available (P =.009), but if a protocol was available they were more likely to be eligible for enrollment (P <.001). Significantly more protocols were available for patients with non-small-cell lung cancer (NSCLC) compared with those who had small-cell lung cancer (SCLC) (63% vs. 48%; P <.001). Patients with advanced disease were more likely to have a protocol available (P <.001) and enter a study (P =.031). The most common reasons for patients not being eligible for enrollment were poor performance status (32%) and presence of comorbid disease (27%). The most common reasons for potentially eligible patients not enrolling in a study included preference for treatment closer to home (49%) and patient refusal (43%). Conclusion: Additional strategies are required to increase accrual of patients into lung cancer trials, including development of protocols for early-stage disease and modifying eligibility and performance status criteria for this unique patient population.

Original languageEnglish (US)
Pages (from-to)14-18
Number of pages5
JournalClinical Lung Cancer
Volume14
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Lung Neoplasms
Clinical Trials
Neoplasms
Medical Oncology
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Thorax
Smoking

Keywords

  • Clinical trials
  • Eligibility
  • Enrollment
  • NSCLC
  • SCLC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. / Horn, Leora; Keedy, Vicki L.; Campbell, Norma; Garcia, Gabe; Hayes, Amy; Spencer, Brady; Carbone, David P.; Sandler, Alan; Johnson, David H.

In: Clinical Lung Cancer, Vol. 14, No. 1, 01.2013, p. 14-18.

Research output: Contribution to journalArticle

Horn, L, Keedy, VL, Campbell, N, Garcia, G, Hayes, A, Spencer, B, Carbone, DP, Sandler, A & Johnson, DH 2013, 'Identifying barriers associated with enrollment of patients with lung cancer into clinical trials', Clinical Lung Cancer, vol. 14, no. 1, pp. 14-18. https://doi.org/10.1016/j.cllc.2012.03.008
Horn, Leora ; Keedy, Vicki L. ; Campbell, Norma ; Garcia, Gabe ; Hayes, Amy ; Spencer, Brady ; Carbone, David P. ; Sandler, Alan ; Johnson, David H. / Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. In: Clinical Lung Cancer. 2013 ; Vol. 14, No. 1. pp. 14-18.
@article{e34bccc1ed08469cbc09252c070ec375,
title = "Identifying barriers associated with enrollment of patients with lung cancer into clinical trials",
abstract = "Background: Enrollment of patients with lung cancer into clinical trials is required to accelerate the pace of new therapy development and contribute to a better understanding of the biological characteristics of cancer. Methods: We conducted a retrospective chart review of all patients seen by the thoracic medical oncology team at the Vanderbilt Ingram Cancer Center (VICC) from November 2005 to November 2008 to determine the barriers associated with patient enrollment in to clinical trials. Results: One thousand forty-three patient charts were audited: 32{\%} of patients were eligible for enrollment, and 14{\%} enrolled in a study. There were no significant differences in protocol availability or eligibility by sex, smoking status, or age. Patients living further from the cancer center were significantly less likely to have a study protocol available (P =.009), but if a protocol was available they were more likely to be eligible for enrollment (P <.001). Significantly more protocols were available for patients with non-small-cell lung cancer (NSCLC) compared with those who had small-cell lung cancer (SCLC) (63{\%} vs. 48{\%}; P <.001). Patients with advanced disease were more likely to have a protocol available (P <.001) and enter a study (P =.031). The most common reasons for patients not being eligible for enrollment were poor performance status (32{\%}) and presence of comorbid disease (27{\%}). The most common reasons for potentially eligible patients not enrolling in a study included preference for treatment closer to home (49{\%}) and patient refusal (43{\%}). Conclusion: Additional strategies are required to increase accrual of patients into lung cancer trials, including development of protocols for early-stage disease and modifying eligibility and performance status criteria for this unique patient population.",
keywords = "Clinical trials, Eligibility, Enrollment, NSCLC, SCLC",
author = "Leora Horn and Keedy, {Vicki L.} and Norma Campbell and Gabe Garcia and Amy Hayes and Brady Spencer and Carbone, {David P.} and Alan Sandler and Johnson, {David H.}",
year = "2013",
month = "1",
doi = "10.1016/j.cllc.2012.03.008",
language = "English (US)",
volume = "14",
pages = "14--18",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Identifying barriers associated with enrollment of patients with lung cancer into clinical trials

AU - Horn, Leora

AU - Keedy, Vicki L.

AU - Campbell, Norma

AU - Garcia, Gabe

AU - Hayes, Amy

AU - Spencer, Brady

AU - Carbone, David P.

AU - Sandler, Alan

AU - Johnson, David H.

PY - 2013/1

Y1 - 2013/1

N2 - Background: Enrollment of patients with lung cancer into clinical trials is required to accelerate the pace of new therapy development and contribute to a better understanding of the biological characteristics of cancer. Methods: We conducted a retrospective chart review of all patients seen by the thoracic medical oncology team at the Vanderbilt Ingram Cancer Center (VICC) from November 2005 to November 2008 to determine the barriers associated with patient enrollment in to clinical trials. Results: One thousand forty-three patient charts were audited: 32% of patients were eligible for enrollment, and 14% enrolled in a study. There were no significant differences in protocol availability or eligibility by sex, smoking status, or age. Patients living further from the cancer center were significantly less likely to have a study protocol available (P =.009), but if a protocol was available they were more likely to be eligible for enrollment (P <.001). Significantly more protocols were available for patients with non-small-cell lung cancer (NSCLC) compared with those who had small-cell lung cancer (SCLC) (63% vs. 48%; P <.001). Patients with advanced disease were more likely to have a protocol available (P <.001) and enter a study (P =.031). The most common reasons for patients not being eligible for enrollment were poor performance status (32%) and presence of comorbid disease (27%). The most common reasons for potentially eligible patients not enrolling in a study included preference for treatment closer to home (49%) and patient refusal (43%). Conclusion: Additional strategies are required to increase accrual of patients into lung cancer trials, including development of protocols for early-stage disease and modifying eligibility and performance status criteria for this unique patient population.

AB - Background: Enrollment of patients with lung cancer into clinical trials is required to accelerate the pace of new therapy development and contribute to a better understanding of the biological characteristics of cancer. Methods: We conducted a retrospective chart review of all patients seen by the thoracic medical oncology team at the Vanderbilt Ingram Cancer Center (VICC) from November 2005 to November 2008 to determine the barriers associated with patient enrollment in to clinical trials. Results: One thousand forty-three patient charts were audited: 32% of patients were eligible for enrollment, and 14% enrolled in a study. There were no significant differences in protocol availability or eligibility by sex, smoking status, or age. Patients living further from the cancer center were significantly less likely to have a study protocol available (P =.009), but if a protocol was available they were more likely to be eligible for enrollment (P <.001). Significantly more protocols were available for patients with non-small-cell lung cancer (NSCLC) compared with those who had small-cell lung cancer (SCLC) (63% vs. 48%; P <.001). Patients with advanced disease were more likely to have a protocol available (P <.001) and enter a study (P =.031). The most common reasons for patients not being eligible for enrollment were poor performance status (32%) and presence of comorbid disease (27%). The most common reasons for potentially eligible patients not enrolling in a study included preference for treatment closer to home (49%) and patient refusal (43%). Conclusion: Additional strategies are required to increase accrual of patients into lung cancer trials, including development of protocols for early-stage disease and modifying eligibility and performance status criteria for this unique patient population.

KW - Clinical trials

KW - Eligibility

KW - Enrollment

KW - NSCLC

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=84871576568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871576568&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2012.03.008

DO - 10.1016/j.cllc.2012.03.008

M3 - Article

C2 - 22591607

AN - SCOPUS:84871576568

VL - 14

SP - 14

EP - 18

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -